Study Of Regulations For Generic Drug Approval In Myanmar, Malaysia, Madagascar And India

Generic drugs are medications that are the same as brand-name drugs in dosage form, safety, strength, quality, and intended use, but are typically less expensive. They become available after the original brand-name drug's patent expires and must meet the same strict standards as the brand-name product for approval. Generic drugs contain the same active ingredients, have the same bioequivalence, and provide the same clinical benefit, though they may differ in inactive ingredients, colour, shape, and flavour.Generic drug product is comparable to an innovator drug product in following cases:

1. Dosage form

2. Strength

3. Route of administration

4. Quality

5. Intended Use 

MYANMAR

In Myanmar, the regulation of pharmaceuticals, including generic drugs, is overseen by the Ministry of Health (MoH) through the Food and Drug Administration (FDA-Myanmar). Over recent years, Myanmar has strengthened its regulatory infrastructure to align more closely with global regulatory best practices, the ASEAN Common Technical Dossier (ACTD) format, and harmonized guidelines under the ASEAN Pharmaceutical Product Working Group (PPWG). The registration process for generic drugs in Myanmar requires submission of comprehensive administrative, quality, non-clinical, and clinical evidence, including proof of bioequivalence, manufacturing compliance with Good Manufacturing Practices (GMP), and product safety data. ^[1]

MALAYSIA

In Malaysia, the system for regulating medicines is managed by the National Pharmaceutical Regulatory Agency (NPRA) under the Ministry of Health (MOH). NPRA is responsible for checking the safety, quality, and effectiveness of generic medicines. Malaysia follows the Control of Drugs and Cosmetics Regulations 1984 and uses the ASEAN Common Technical Dossier (ACTD) format for submissions. It also requires GMP certification and bioequivalence studies to ensure generics are equal to the original products. ^[2]

MADAGASCAR

In Madagascar, the regulation of pharmaceuticals, including generic medicines, is under the authority of the Ministry of Public Health through the Madagascar Drug’s Agency (Agence du Medicament de Madagascar). The country has established a structured regulatory system to ensure the medical and technical evaluation of registration dossiers as an essential step in guaranteeing the quality of medicines placed on the market. The national registration procedures are designed to comply with current regulations and provide a common registration process for pharmaceutical sector operators. Applicants are required to submit comprehensive administrative, pharmaceutical, analytical, biological, and clinical documentation, along with evidence of Good Manufacturing Practices (GMP), product quality, safety, and efficacy, to support the granting of Marketing Authorization (MA). ^[3]

INDIA

Generic drug approval in India is handled by the Central Drugs Standard Control Organization (CDSCO), which requires an abbreviated new drug application (ANDA) for a generic drug to prove it is bioequivalent to the original product. While the applicant doesn't need to resubmit preclinical and clinical trial data for safety and efficacy, the generic drug must meet quality standards, and the application must be approved by the CDSCO before it can be marketed in India. ^[4]

MYANMAR 

Generic Drug Registration Process In Myanmar ^[5]

Myanmar's drug regulatory authority is the Food and Drug Administration (FDA), operating under the Ministry of Health, responsible for ensuring the safety, quality, and efficacy of food, drugs, cosmetics, and medical devices, using the ASEAN Common Technical Dossier (ACTD) format for drug registration, requiring local representation and an online portal for submissions, with registrations typically valid for five years. 

Application dossier requirements

The application dossier for registration has to comply with the ASEAN Common Technical Dossier format. Generic drugs dossier contains Part I (Administrative documents and product information) and Part II documentation (Quality documents for drug substance and drug product).

Application must be submitted in person by:

• • Authorized representative of the manufacturer/owner of the drug.
  • Representative must be a resident in Myanmar.

Local company representatives must be technically competent employees.

Registration Dossier Structure

The Dossier consist of Four parts, each covering a specific set of data. The dossier required for the generic drug

To register generic drugs in Myanmar documents require

1. Application (Form 1),
2. A letter of authorization for legal representation of manufacturer (owner of product) in Myanmar.
3. The manufacturer's GMP Certificate,
4. Manufacturing License,
5. Certificate of Pharmaceutical Product (CPP), 
6. A detailed dossier (ASEAN CTD format) covering quality (composition, specs, stability, analysis) and
7. Labelling/packaging details

Registration Process ^[5]

The process to register for the generic product can be summarized into the following steps

Prerequisites for submission of application

• The first step is to submit the list of products to the FDA for which the applicant intends to apply for registration. 
• After that, the FDA issues a letter for assessment fee payment.
• If the application is to register drugs manufactured overseas, the applicant has to request FDA for the import of drug samples.
• Applicants have to submit samples to FDA before submission of the application and within one week from the date of clearance. FDA checks the sample and issues a receipt with the date and reception number. ^[1]

Submission Of Application:

The applicant has to start a new application and needs to obtain an application number automatically. The applicant needs to consider the following points to make an application.

Evaluation And Approval:

• After submission, the DFDA-DCS screens the application and notifies the applicant about the verification outcomes.
• If the FDA approves the drug, it issues a letter of payment of registration fees for the issuance of the drug registration certificate.
• The applicant has to complete the payment within 90 days and upload the receipt through the online system.

Form For Registration:

• Form 1 (Registration) is mandatory.
• Cost: 1,000 Kyats per form.
• Must be filled in typed or capital letters; incomplete forms not accepted.

Approval Timeline:

In Myanmar, the generic drug registration process usually requires approximately 6-12 months. Validity of registration is 5 years. ^[6]

Fees Required For Registration:

• Registration Assessment Fee: 300,000 Kyats
  (to be paid before dossier acceptance)

• Registration Fee: 500,000 Kyats
  (If not paid within 90 days, then application considered forfeited)

MALAYSIA

Malaysia's drug regulatory authority is the National Pharmaceutical Regulatory Agency (NPRA), operating under the Ministry of Health (MOH), responsible for ensuring the quality, safety, and efficacy of medicines, health supplements, traditional products, and cosmetics through registration, licensing, and post-market surveillance (pharmacovigilance) to protect public health

Generic Drug Registration Process In Malaysia

Types of generic drugs in Malaysia

Generics are classified into two groups

1. Scheduled Poison (Known as Controlled Medicine/ Controlled Poison).
   • Products containing poisons as listed in the First Schedule under the Poisons Act 1952.
2. Non-scheduled Poison (Known as Non-Poison or “Over the Counter” OTC).
   • Products containing active ingredients that are not listed in the First Schedule under the Poisons Act 1952; and excluding active ingredient which is categorized under health supplements natural products or cosmetics.

Documents Require:

1. Good Manufacturing Practice (GMP) certificate
2. Certificate of Pharmaceutical Product (CPP) If the product is imported (i.e. manufactured outside Malaysia)
3. API-related documentation if Manufacturer uses an Active Pharmaceutical Ingredient (API) sourced from outside, NPRA may require documents such as a Drug Master File (DMF) or relevant certificate.
4. A detailed dossier (ASEAN CTD format)
5. Labelling/packaging details
6. Zone IVB Stability data
7. Process Validation Report (according to ASEAN Guidelines).
8. Analytical Validation Report (according to ASEAN Guidelines) and Analytical procedure.
9. Bioequivalence (BE) Study Report for Generic Products (according to ASEAN Guidelines). ^[7]

Registration Process: ^{[8, 9, 10]}

Fees Required For Registration:  RM 2200-RM3000 (51,371-70,052 INR)

MADAGASCAR ^{[3, 11]}

Generic Drug Registration Process In Madagascar

1. Submission of Application (MA)
   Submit dossier to the Director of the Madagascar Drug’s Agency including an application letter, SPC, GMP certificate, and other required documents.
2. Administrative Documentation
   Provide GMP certificate, valid MA from country of origin, CPP (WHO format), list of approved countries, etc.
3. Pharmaceutical & Analytical Data
   Submit specifications, manufacturing formula, in-process controls, certificates of analysis, and validated analytical methods.
4. Stability Studies
   Provide real-time and accelerated stability data, data from three batches, and stability protocol signed by the manufacturer.
5. Clinical/Bioequivalence & Safety Data
   Submit clinical/bioequivalence study data (if needed), evidence of safety, quality, and efficacy, and pharmacovigilance information.
6. Sample Submission
   Submit product samples according to dosage form, accompanied by a certificate of analysis.
7. Evaluation by Madagascar Drug’s Agency
   Administrative, quality, safety, and GMP compliance assessment.
   Incomplete applications are inadmissible.
8. Grant of Marketing Authorization (MA)
   If acceptable, MA is granted.
   • Regulatory Authority: Madagascar Drug’s Agency, Ministry of Public Health
   • MA Process Timeline:
     • New MA: 4 months
     • Renewal/Variation: 2 months
9. Fees for Generic Registration

For Imported Drugs 200 € (18000 INR)

Locally Manufactured Drugs 164,000 MGA (3372 INR)

Documents Required For Registration Process:

1. Administrative Documents

• Application letter for Marketing Authorization (MA) addressed to the Director of Madagascar Drug’s Agency
• Summary of Product Characteristics (SPC)
• Appointment letter of official local representative in Madagascar (with contact details)
• Certified copy of GMP Certificate of manufacturer (valid, issued by competent authority)
• Certified copy of Marketing Authorization from country of origin
• Free Sale Certificate
• WHO-format Certificate of Pharmaceutical Product (CPP)
• Commitment letter signed by the responsible pharmacist
• List of countries where the product is approved and marketed (with copies of licenses)
• Draft label and packaging artwork for each product
• WHO prequalification certificate (optional)

2. Pharmaceutical (Quality) Documents

• Origin of raw materials and manufacturer information
• Raw material, intermediate and finished product specifications
• Manufacturing formula
• Manufacturing process description
• In-process control procedures (clarifying role of excipients)

3. Analytical Documents

• Certificates of analysis (CoA) of raw materials
• Certificate of analysis of finished product (same batch as samples)
• Analytical test methods
• Validation of analytical methods (especially in-house methods)

4. Stability Data

• Stability study protocol
• Real-time stability results
• Accelerated stability results
• Data on three different batches

5. Clinical / Bioequivalence / Safety Data

• For new active ingredients or new combinations: toxicological, pharmacological, and clinical data
• For generics: justification of safety and efficacy based on reference product
• Pharmacovigilance file
• Post-marketing adverse reaction data (if available)
• Risk Management Plan (for new actives or combinations)

6. Sample Requirements

Samples must be:

• In original packaging
• From the same batch
• Accompanied by certificate of analysis

(Quantities depend on dosage form such as tablets, capsules, injections, creams, suspensions, etc.)

7. Language & Format Requirements

• Dossiers must be in French or English
• Documents must follow the order presented in the registration manual
• Incomplete MA applications are inadmissible

INDIA

Registration Process In India

India's national regulatory body under the Ministry of Health, ensuring drug, cosmetic, and medical device quality, safety, and efficacy by regulating imports, new drug approvals, clinical trials, and licensing, working with state regulators for uniform enforcement nationwide from its New Delhi HQ, with zonal/port offices and labs across India.The generic drug registration process in India involves submitting an Abbreviated New Drug Application (ANDA) via the CDSCO SUGAM portal, providing a Common Technical Document (CTD) with CMC data, and crucially, conducting Bioequivalence (BE) studies to prove sameness to the reference drug, followed by technical review, potential site inspection, and final marketing approval, aiming for a 180-day timeline for faster approvals. 

Documents Require For Registration Of Generic Drug In India:

1. Administrative / Applicant details
   • • Name & address of applicant; name & address of manufacturer(s) and manufacturing site(s).
     • Cover letter indicating type of application (import/manufacture etc.)
     • Original Power of Attorney (if Indian agent involved) — executed and attested properly.
2. Drug Identity & Formulation Details

• Generic name, brand name (if any).
• Dosage form (tablet, capsule, injection, syrup, etc.).
• Composition: qualitative & quantitative particulars of all constituents (active + excipients / inactive ingredients).

3. Quality / Chemistry-Manufacturing-Control (CMC) Data
   • • Detailed manufacturing process, flow charts, in-process controls.
     • Batch manufacturing record and process validation reports.
     • Analytical methods & full specifications / monograph methods (for identification, assay, impurities, residual solvents, related substances etc.).
     • Certificate of Analysis (CoA) for at least 3 batches.
     • Stability data for three different lots (e.g. per Schedule-Y requirements: batch number, manufacturing date, packaging, storage conditions, expiry/retention data).
     • Material Safety Data Sheet (MSDS) for substances, if applicable.
     • Reference product characterization (if copying an already approved drug).
     • Draft / proposed labelling and packaging details, including label copy.
4. Therapeutic / Regulatory Information
   • • Therapeutic class / pharmacological classification, indication(s) proposed, dosage strength(s).
     • Date of first approval of the parent / bulk drug (if applying for subsequent approval/import of a known drug).
5. Forms & Regulatory Submissions
   • • Duly filled and signed Form 44 (for manufacturing/import/marketing).
     • Treasury challan / proof of fee payment

Approval Process For Drug Substance /Drug Product Approved By DCGI Within A Period Of Four Years From The Date Of Its First Approval.

Fees And Time: ^[12]

Generic drug registration costs INR 15,000.

6 to 12 months from submission.

COMPARATIVE TABLE OF MYANMAR, MALAYSIA, MADAGASCAR AND INDIA: